NASDAQ:BLPH Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis $0.05 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.05▼$0.0550-Day Range$0.05▼$0.0752-Week Range$0.03▼$0.52Volume80 shsAverage Volume9,160 shsMarket Capitalization$623,730.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsSustainabilityTrends Get Bellerophon Therapeutics alerts: Email Address Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About Bellerophon Therapeutics Stock (NASDAQ:BLPH)Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Read More BLPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLPH Stock News HeadlinesJuly 21, 2024 | americanbankingnews.comBellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at StockNews.comJuly 20, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)July 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...February 25, 2024 | uk.finance.yahoo.comBellerophon Therapeutics, Inc. (BLPH)February 15, 2024 | investing.comBellerophon Therapeutics Inc (BLPH)January 31, 2024 | msn.comBellerophon Offers Series A Stock in Private SaleNovember 28, 2023 | benzinga.comHilco Streambank Seeks Offers to Acquire Patent Portfolio and Material Inventory of Biotherapeutics Company BellerophonNovember 2, 2023 | morningstar.comBellerophon Therapeutics Inc BLPHJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...August 8, 2023 | finance.yahoo.comBLPH - Bellerophon Therapeutics, Inc.July 25, 2023 | msn.comWhat's Happening With Bellerophon Therapeutics Stock Today?July 25, 2023 | investorplace.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?July 6, 2023 | msn.comBellerophon Therapeutics (BLPH) Price Target Decreased by 92.23% to 2.04June 6, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Bellerophon TherapeuticsJune 6, 2023 | finance.yahoo.comIs Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?June 6, 2023 | msn.comLaidlaw & Co. Downgrades Bellerophon Therapeutics (BLPH)June 6, 2023 | msn.comHC Wainwright & Co. Maintains Bellerophon Therapeutics (BLPH) Buy RecommendationJune 5, 2023 | msn.comBellerophon Therapeutics Stock Nosedive: Here's WhySee More Headlines Receive BLPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2023Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLPH CUSIPN/A CIK1600132 Webwww.bellerophon.com Phone(908) 574-4770FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book0.19Miscellaneous Outstanding Shares12,230,000Free Float11,597,000Market Cap$623,730.00 OptionableNo Data Beta0.73 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Craig R. Jalbert CIRA (Age 62)President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director Key CompetitorsQuoin PharmaceuticalsNASDAQ:QNRXCyclacel PharmaceuticalsNASDAQ:CYCCInMed PharmaceuticalsNASDAQ:INMNexImmuneNASDAQ:NEXI60 Degrees PharmaceuticalsNASDAQ:SXTPView All CompetitorsInsidersPuissance Capital Management LSold 1,076,841 sharesTotal: $107,684.10 ($0.10/share)View All Insider Transactions BLPH Stock Analysis - Frequently Asked Questions How have BLPH shares performed this year? Bellerophon Therapeutics' stock was trading at $0.0370 on January 1st, 2024. Since then, BLPH stock has increased by 37.8% and is now trading at $0.0510. View the best growth stocks for 2024 here. How were Bellerophon Therapeutics' earnings last quarter? Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) EPS for the quarter. When did Bellerophon Therapeutics' stock split? Bellerophon Therapeutics shares reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Bellerophon Therapeutics IPO? Bellerophon Therapeutics (BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers. How do I buy shares of Bellerophon Therapeutics? Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bellerophon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM) and Gilead Sciences (GILD). This page (NASDAQ:BLPH) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellerophon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
